April 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Mohamed Rawy: VTE Recommendations in Critical Care Patients

Mohamed Rawy/LinkedIn

Dec 29, 2025, 07:20

Mohamed Rawy: VTE Recommendations in Critical Care Patients

Mohamed Rawy, Hospital Pharmacist at Specialized Medical Center Hospital, shared on LinkedIn:

”From Paper to Patient … Episode 2 ( Part 1 )

Venous Thromboembolism recommendations in Critical Care Patients

First, pharmacologic thromboprophylaxis remains the cornerstone of VTE prevention in ICU
Second, LMWH is generally preferred over UFH since that LMWH probably reduces DVT compared to UFH
The dosing definitions encom passed a range of doses rather than a single fixed dose , The authors suggested that using an intermediate dose
of LMWH (e.g., enoxaparin 40–60 mg daily) was associated with a more favorable risk–benefit profile for VTE prevention compared to lower doses (e.g., < 40 mg daily, low-to-moderate certainty). Additionally, intermediate
dose unfractionated heparin (total daily dose > 10,000 IU) was associated with a higher likelihood of major bleeding (low-to-moderate certainty)
Fourth, when using LMWH for thromboprophylaxis, there is no need for routine monitoring of anti-Factor Xa (aFXa) levels. However, in selected patients, such as those with renal impairment, severe obesity or under
weight, aFXa levels could be used to guide dosing
Fifth, intermittent pneumatic compression should be used in patients who cannot receive pharmacologic thromboprophylaxis
Sixth, there is no added benefit of routinely using intermittent pneumatic compression in patients already receiving appropriate pharmacologic thromboprophylaxis
Seventh, intermittent pneumatic compression reduces the incidence of DVT when compared to graduated compression stockings (GCS) based on low certainty of evidence
Eighth, intensivists should carefully balance the benefits of preventing VTE against the risk of bleeding
Ninth, thromboprophylaxis in the ICU can be discontinued once the patient is no longer at high risk for VTE
Tenth, certain clinical scenarios warrant specific VTE regimens, which should be guided by dedicated evidence-based references